miRNAs in Critical Limb Ischemia (miRNACLI)

Sponsor
IRCCS Policlinico S. Donato (Other)
Overall Status
Recruiting
CT.gov ID
NCT06066268
Collaborator
(none)
80
1
120
0.7

Study Details

Study Description

Brief Summary

For the present study, 40 patients affected by critical limb ischemia of different severity will be enrolled: patients affected by critical limb ischemia undergoing subgenual femoropopliteal bypass; patients suffering from terminal ischemia causing gangrene and therefore undergoing major amputation of the lower limb. Biopsies from the first 20 enrolled patients will be used for miRNA profiling. The total of 40 biopsies obtained from all enrolled patients will instead be used for the validation of the miRNAs identified in the profiling.

The results obtained will be compared with those obtained in 40 control patients affected by infrarenal abdominal aortic aneurysm (AAA) undergoing endovascular exclusion surgery (EVAR) of the AAA without any ischemia of the lower limbs. Also in this case the biopsies of the first 20 control patients enrolled will be used for miRNA profiling. The total of 40 biopsies obtained from all control patients will instead be used for the validation of the miRNAs identified in the profiling. A total of 80 patients (40 cases and 40 controls) will be enrolled.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Critical limb ischemia: analysis of RNAs
  • Diagnostic Test: Controls: analysis of RNAs

Detailed Description

The analyzes of the expression of miRNAs and the RISC complex will be carried out on fragments of skeletal muscle taken from different sites depending on whether they are cases or controls.

Cases:
  • Patients suffering from CLI undergoing lower limb revascularization via subgenual femoropopliteal bypass: Gastrocnemius muscle biopsies will be taken.

  • Patients suffering from terminal CLI and/or gangrene of the lower limb undergoing thigh amputation: biopsies will be taken in different muscle districts. In particular, biopsies of the Sartorius or Vastus lateralis muscle will be taken at the amputation site, both from the proximal muscle belly which remains covering the bone stump, and from the part of the muscle belly sacrificed with the amputated limb. Biopsies of the Gastrocnemius and Tibialis anterior muscles will be taken from the amputated leg.

  • Patients suffering from terminal CLI and/or gangrene of the lower limb undergoing leg amputation: biopsies will be taken in different muscle districts. In particular, biopsies of the Gastrocnemius and Tibialis anterior muscles will be carried out at the amputation site, both from the proximal muscle belly which remains covering the bone stump, and from the part of the muscle belly sacrificed with the amputated limb.

Controls:

• The control subjects will be represented by individuals affected by infrarenal abdominal aortic aneurysm (AAA) free from CLI, affected and not affected by type 2 diabetes mellitus, undergoing endovascular exclusion surgery of the AAA (EVAR), similar by age and sex to CLI patients. Sartorius muscle biopsies will be taken.

The analyzes of the expression of circulating miRNAs will be carried out on 2 7 ml tubes of peripheral venous blood, taken before the surgical incision from the same cases and controls described in the previous point.

Study Design

Study Type:
Observational
Anticipated Enrollment :
80 participants
Observational Model:
Case-Control
Time Perspective:
Retrospective
Official Title:
Role of microRNAs in Critical Limb Ischemia
Actual Study Start Date :
May 31, 2016
Anticipated Primary Completion Date :
May 31, 2026
Anticipated Study Completion Date :
May 31, 2026

Arms and Interventions

Arm Intervention/Treatment
1) Critical limb ischemia (CLI);

1)Critical limb ischemia (CLI): Patients suffering from CLI undergoing lower limb revascularization via subgenual femoropopliteal bypass. muscle biopsies willbe taken. Patients suffering from terminal CLI and/or gangrene of the lower limb undergoing thigh amputation. Muscle biopsies will be taken. Patients suffering from terminal CLI and/or gangrene of the lower limb undergoing leg amputation. Muscle biopsies will be taken.

Diagnostic Test: Critical limb ischemia: analysis of RNAs
analysis of miRNA expression levels

2)Controls

2)Controls: patients affected by infrarenal abdominal aortic aneurysm (AAA) free from CLI, affected and not affected by type 2 diabetes mellitus, undergoing endovascular exclusion surgery of the AAA (EVAR), similar by age and sex to CLI patients. Sartorius muscle biopsies will be taken.

Diagnostic Test: Controls: analysis of RNAs
analysis of miRNAs expression levels

Outcome Measures

Primary Outcome Measures

  1. Identification of potentially pathogenic miRNAs in CLI and related target mRNAs. [1 year to 10 years]

    Identify miRNAs and their targets that directly interact with the RNA Induced Silencing Complex (RISC) in muscle biopsies obtained from CLI patients.

  2. Identification of disease biomarkers [1 year to 10 years]

    Identify plasma miRNAs to be used as disease biomarkers that can be used to assess disease status and severity with a minimally invasive procedure.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 85 Years
Sexes Eligible for Study:
All
Inclusion Criteria:

Cases: patients affected by CLI candidates for popliteal exploration surgery and/or subgenual femoropopliteal bypass. Patients affected by CLI with irreversible ischemia and/or distal gangrene of the lower limb candidates for major amputation of the lower limb.

Controls: patients affected by infrarenal abdominal aortic aneurysm (AAA) undergoing endovascular exclusion surgery of the AAA (EVAR) who are free from CLI, affected and not affected by type 2 diabetes mellitus.

Exclusion Criteria:
  • Pregnant women

  • Patients carriers of genetic diseases

  • Patients suffering from malignant neoplasia

Contacts and Locations

Locations

Site City State Country Postal Code
1 Irccs Policlinico San Donato San Donato Milanese Milan Italy 20097

Sponsors and Collaborators

  • IRCCS Policlinico S. Donato

Investigators

  • Principal Investigator: Fabio Martelli, IRCCS Policlinico S. Donato

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Fabio Martelli, Dr., IRCCS Policlinico S. Donato
ClinicalTrials.gov Identifier:
NCT06066268
Other Study ID Numbers:
  • miRNACLI
First Posted:
Oct 4, 2023
Last Update Posted:
Oct 4, 2023
Last Verified:
Sep 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Fabio Martelli, Dr., IRCCS Policlinico S. Donato
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 4, 2023